SG11201608120TA - Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage - Google Patents

Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage

Info

Publication number
SG11201608120TA
SG11201608120TA SG11201608120TA SG11201608120TA SG11201608120TA SG 11201608120T A SG11201608120T A SG 11201608120TA SG 11201608120T A SG11201608120T A SG 11201608120TA SG 11201608120T A SG11201608120T A SG 11201608120TA SG 11201608120T A SG11201608120T A SG 11201608120TA
Authority
SG
Singapore
Prior art keywords
immunoglobulin
peptide
protein
improving solubility
fragment linkage
Prior art date
Application number
SG11201608120TA
Inventor
Hyung Kyu Lim
Jong Soo Lee
Dae Jin Kim
Sung Min Bae
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of SG11201608120TA publication Critical patent/SG11201608120TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201608120TA 2014-03-31 2015-03-31 Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage SG11201608120TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140038032 2014-03-31
PCT/KR2015/003195 WO2015152618A1 (en) 2014-03-31 2015-03-31 Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage

Publications (1)

Publication Number Publication Date
SG11201608120TA true SG11201608120TA (en) 2016-11-29

Family

ID=54240858

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608120TA SG11201608120TA (en) 2014-03-31 2015-03-31 Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
SG10202107752PA SG10202107752PA (en) 2014-03-31 2015-03-31 Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202107752PA SG10202107752PA (en) 2014-03-31 2015-03-31 Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage

Country Status (21)

Country Link
US (2) US20170128589A1 (en)
EP (2) EP3127923B1 (en)
JP (3) JP2017511335A (en)
KR (2) KR102385120B1 (en)
CN (2) CN117065044A (en)
AU (1) AU2015242657B2 (en)
CA (1) CA2944138C (en)
DK (1) DK3127923T3 (en)
EA (1) EA201691795A1 (en)
ES (1) ES2897935T3 (en)
HU (1) HU231358B1 (en)
IL (1) IL248111B (en)
MX (1) MX2016012788A (en)
MY (1) MY192248A (en)
NO (1) NO20161667A1 (en)
PH (1) PH12016501937A1 (en)
PL (1) PL3127923T3 (en)
SG (2) SG11201608120TA (en)
UA (1) UA124182C2 (en)
WO (1) WO2015152618A1 (en)
ZA (1) ZA201607344B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152618A1 (en) * 2014-03-31 2015-10-08 한미약품 주식회사 Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
CN109069569B (en) * 2015-12-02 2023-02-14 韩美药品株式会社 Protein conjugates using fatty acid derivatives and methods of making the same
CA3052410A1 (en) * 2017-02-03 2018-08-09 Hanmi Pharm. Co., Ltd. Conjugate of bioactive material having enhanced sustainability and use thereof
CN106892978A (en) * 2017-04-18 2017-06-27 天津世传生物科技有限公司 Compound, protein and the preparation method of the two
IL299892A (en) 2017-06-20 2023-03-01 Madrigal Pharmaceuticals Inc Combination therapies comprising targeted therapeutics
KR102053009B1 (en) * 2018-09-19 2019-12-09 주식회사 바이오앱 Vaccine composition for classical swine fever and manufacturing method thereof
KR102250576B1 (en) 2018-11-15 2021-05-12 주식회사 바이오앱 Recombinant vector to increase the expression of capsid protein in plant expression system and virus-like particles preparation method using the same
WO2020101187A1 (en) 2018-11-15 2020-05-22 주식회사 바이오앱 Recombinant vector for expressing virus-like particles in plant and method for preparation of vaccine composition containing circovirus-like particles by using same
KR102288367B1 (en) 2018-11-15 2021-08-11 주식회사 바이오앱 Recombinant vector expressing virus-like particles in plants and methods of preparing vaccine compositions comprising circovirus-like particles using the same
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
US20230265160A1 (en) * 2019-09-06 2023-08-24 Novartis Ag Therapeutic fusion proteins
WO2022080912A1 (en) * 2020-10-16 2022-04-21 주식회사 아이엠바이오로직스 Fusion protein platform using igm region
KR20220122815A (en) 2021-02-25 2022-09-05 주식회사 바이오앱 Method for manufacturing alfalfa mosaic virus-like particles using plant expression system and application thereof
KR20240027904A (en) 2022-08-22 2024-03-05 (주) 에빅스젠 Peptide for improving solubility and composition for improved solubility comprising the same

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
DK1724284T3 (en) * 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusion proteins
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
ATE525395T1 (en) * 2003-06-12 2011-10-15 Lilly Co Eli FUSION PROTEINS OF GLP-1 ANALOGS
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
UA87009C2 (en) * 2004-12-22 2009-06-10 Эли Лилли Энд Компани Glp-1 analog fusion protein formulations
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
KR100755315B1 (en) 2005-04-11 2007-09-05 엘지전자 주식회사 Multi-Air conditioner system and the operating methode of the same
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8658174B2 (en) * 2005-07-27 2014-02-25 Qinghua Wang GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
KR100824505B1 (en) 2005-08-16 2008-04-22 한미약품 주식회사 A METHOD FOR THE MASS PRODUCTION OF IMMUNOGLOBULIN Fc REGION DELETED INITIAL METHIONINE RESIDUES
JP2008169195A (en) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd Insulinotopic peptide drug combo using carrier material
ES2623925T3 (en) * 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Immunoglobulin Fusion Proteins
JP2009019027A (en) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
CN101820913A (en) * 2007-08-09 2010-09-01 第一三共株式会社 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
JP2011511778A (en) * 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Ester-based peptide prodrugs
EP2300501B1 (en) * 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
AU2009335712B2 (en) * 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
KR101912335B1 (en) * 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 Glycopolysialylation of non-blood coagulation proteins
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
KR101335765B1 (en) * 2010-01-19 2013-12-02 한미사이언스 주식회사 Liquid formulation for long-acting erythropoietin conjugate
MX340463B (en) * 2010-01-19 2016-07-06 Hanmi Science Co Ltd * Liquid formulations for long-acting g-csf conjugate.
AR081066A1 (en) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
AR081755A1 (en) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd FORMULATION OF PROLONGED ACTION OF THE FOLICULES STIMULATING HORMONE WHERE AN IMMUNOGLOBULIN FRAGMENT, PREPARATION METHOD AND METHOD TO TREAT A SUBJECT SUFFERING A REPRODUCTIVE DISORDER ARE USED
US9981017B2 (en) * 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR080993A1 (en) * 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd FORMULATION OF PROLONGED BETA INTERFERTION ACTION WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
KR101337797B1 (en) * 2010-07-14 2013-12-06 한미사이언스 주식회사 A liquid formulation of long acting human growth hormone conjugate
KR101382593B1 (en) * 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
KR101830344B1 (en) * 2010-10-26 2018-02-22 한미사이언스 주식회사 A fusion protein of a fibronectin fragment and an immunoglobulin fragment and use thereof
KR101303388B1 (en) * 2010-10-26 2013-09-03 한미사이언스 주식회사 Liquid formulations of long acting interferon alpha conjugate
KR20140027129A (en) * 2011-04-04 2014-03-06 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 Peptide which can induce antibody capable of recognizing stereostructure of hiv
UA113626C2 (en) * 2011-06-02 2017-02-27 A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE
BR112013031794B1 (en) 2011-06-10 2020-11-10 Hanmi Science Co., Ltd peptides derived from oxintomodulin and their use, polynucleotide, pharmaceutical composition and their use and method for the prevention or treatment of obesity comprising the same
AU2012270366C1 (en) * 2011-06-17 2017-07-13 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
CA2847837A1 (en) * 2011-09-05 2013-03-14 Hanmi Science Co., Ltd. A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate
EP3417881A1 (en) * 2011-10-06 2018-12-26 Hanmi Science Co., Ltd. Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
KR20130049671A (en) * 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
KR101895047B1 (en) * 2011-12-30 2018-09-06 한미사이언스 주식회사 A site-specific GLP-2 conjugate using an immunoglobulin fragment
KR102041412B1 (en) * 2011-12-30 2019-11-11 한미사이언스 주식회사 Derivatives of Immunglobulin Fc fragment
AR090281A1 (en) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CN103509118B (en) * 2012-06-15 2016-03-23 郭怀祖 insulin-Fc fusion protein
JP6429773B2 (en) * 2012-07-19 2018-11-28 オックスフォード ナノポール テクノロジーズ リミテッド Enzyme construct
AR092862A1 (en) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
US10441665B2 (en) * 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR091902A1 (en) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF A PROLONGED INSULIN CONJUGATE
KR101968344B1 (en) * 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
AR094821A1 (en) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
MX2015005698A (en) * 2012-11-06 2015-08-20 Hanmi Pharm Co Tld Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment.
KR101993393B1 (en) * 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
AR096891A1 (en) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
AR096890A1 (en) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATING FC OF IMMUNOGLOBULINA, THAT MAINTAINS THE UNION AFFINITY OF THE FC FRAGMENT OF THE IMMUNOGLOBULIN TO FCRN
CN114288254A (en) * 2013-09-27 2022-04-08 韩美药品株式会社 Formulations of long-acting human growth hormone conjugates
WO2015152618A1 (en) * 2014-03-31 2015-10-08 한미약품 주식회사 Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
TWI684458B (en) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
KR20150140177A (en) * 2014-06-05 2015-12-15 한미약품 주식회사 Method of decreasing immunogenicity of protein and pepteide
HRP20220995T1 (en) * 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Triple activator activating glucagon, glp-1 and gip receptor
TWI757305B (en) * 2016-06-29 2022-03-11 南韓商韓美藥品股份有限公司 Glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof

Also Published As

Publication number Publication date
EP3889185A2 (en) 2021-10-06
CN117065044A (en) 2023-11-17
IL248111B (en) 2022-04-01
JP7333249B2 (en) 2023-08-24
EA201691795A1 (en) 2017-03-31
PH12016501937A1 (en) 2017-02-06
DK3127923T3 (en) 2021-11-22
PL3127923T3 (en) 2022-01-31
AU2015242657A1 (en) 2016-10-27
NO20161667A1 (en) 2016-10-19
EP3127923A4 (en) 2018-04-18
UA124182C2 (en) 2021-08-04
HU231358B1 (en) 2023-03-28
WO2015152618A1 (en) 2015-10-08
ZA201607344B (en) 2019-04-24
JP7322105B2 (en) 2023-08-07
MX2016012788A (en) 2016-12-12
KR102385120B1 (en) 2022-04-12
JP2020040983A (en) 2020-03-19
HUP1600621A2 (en) 2017-01-30
EP3127923B1 (en) 2021-08-18
CA2944138C (en) 2023-06-20
IL248111A0 (en) 2016-11-30
JP2021167352A (en) 2021-10-21
NZ724926A (en) 2023-11-24
KR20220042326A (en) 2022-04-05
JP2017511335A (en) 2017-04-20
CN106488933A (en) 2017-03-08
US20230220034A1 (en) 2023-07-13
EP3889185A3 (en) 2022-01-26
AU2015242657B2 (en) 2020-05-21
ES2897935T3 (en) 2022-03-03
SG10202107752PA (en) 2021-09-29
KR20150113934A (en) 2015-10-08
US20170128589A1 (en) 2017-05-11
BR112016022844A2 (en) 2017-10-17
EP3127923A1 (en) 2017-02-08
CA2944138A1 (en) 2015-10-08
MY192248A (en) 2022-08-10

Similar Documents

Publication Publication Date Title
ZA201607344B (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
ZA201701810B (en) Sirp-alpha immunoglobulin fusion proteins
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
ZA201608811B (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP3341025A4 (en) Protein complex by use of a specific site of an immunoglobulin fragment for linkage
EP3236772A4 (en) Methods of purifying recombinant proteins
IL249131A0 (en) Method for decreasing immunogenicity of protein and peptide
IL285146A (en) Methods of purifying fc-containing proteins
IL254765A0 (en) Method of monomerisation of recombinant antibody molecules
EP3153581A4 (en) Method for producing recombinant proteins using recombinant brevibacillus
EP3521299A4 (en) Method for purifying recombinant protein
IL255094A0 (en) Method for increasing the percentage of monomeric antibody fab-dsfv multimeric species
PL3363811T3 (en) Method for producing fusion protein having igg fc domain
EP3092002A4 (en) Method of purifying monoclonal antibodies
EP3564254A4 (en) Method for recovering protein
SG11201608659TA (en) Vnar recombinant monoclonal antibodies that neutralize vascular endophelial growth factor vegf
IL247996A0 (en) Method for detecting protein modifications
EP3231441A4 (en) Novel protein structure produced by effective antibody used for immunization
EP3241022A4 (en) Methods for protein and peptide reduction
EP3539992A4 (en) Fragment antibody and method for crystallizing protein using fragment antibody
GB2556396B (en) Method for Hydrolysing protein materials
IL248458A0 (en) Monoclonal antibodies specific for cry1ca and related detection methods
ZA201608812B (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
GB201703416D0 (en) Method for protein expression
EP3170901A4 (en) Method for identifying epitope of protein